Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Hospital, Rochester, Minnesota.
National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, Maryland.
J Pain. 2024 Nov;25(11):104665. doi: 10.1016/j.jpain.2024.104665. Epub 2024 Sep 12.
Nationally representative rates of incident prescription opioid use in the United States adult population and selected subpopulations are unknown. Using the National Health Interview Survey (2019-2020) longitudinal cohort, a cohort with 1-year follow-up created using random cluster probability sampling of noninstitutionalized civilian U.S. adults, we estimated rates and predictors of incident opioid use. Of 21,161 baseline (2019) participants randomly chosen for follow-up, the final analytic sample included 10,415 who also participated in 2020. Exposure variables were selected per the socio-behavioral model of health care utilization: predisposing characteristics (sex, age, race, etc), enabling characteristics (socioeconomic status, insurance status), health status (pain, disability, comorbidities, etc), and health care use (office visits, emergency room visits, and hospitalizations). Among adults who did not use prescription opioids in 2019, a 1-year cumulative incidence of 4.1% (95% confidence interval [CI]: 3.5-4.6) was seen in 2020, with an incidence rate (IR) of 32.6 cases of new prescription opioid use per 1,000 person-years (PYs). Cumulative incidence, IR, and adjusted relative risk (RR) varied by participant characteristics. We observed the highest IR in those with ineffective pain treatment (81.6 cases per 1,000 PY) and those who visited the emergency room ≥3 times (93.8 cases per 1,000 PY). Participants reporting ≥4 painful conditions had an adjusted RR of 2.9 (95% CI: 2.0-4.1), while the RR for those with sleep problems was 2.3 (95% CI: 1.7-3.1). Overall, this study presents nationally representative rates of incident prescription opioid use and suggests that some participants are using prescription opioids as an early-resort analgesic contrary to best-practice guidelines. PERSPECTIVE: This longitudinal cohort study presents nationally representative rates of incident prescription opioid use in U.S. adults and selected subpopulations. Our data suggest that some participants are using prescription opioids as a first-line or early-resort analgesic, contrary to best-practice guidelines.
在美国成年人群体和选定的亚人群中,全国范围内新发生的处方阿片类药物使用的代表性比率尚不清楚。本研究使用了全国健康访谈调查(2019-2020 年)的纵向队列数据,这是一个通过对非住院的美国成年平民进行随机聚类概率抽样而创建的具有 1 年随访的队列。我们估算了新发生阿片类药物使用的比率和预测因素。在随机选择的 21161 名基线(2019 年)参与者中,最终分析样本包括了 10415 名在 2020 年也参与了调查的参与者。暴露变量是根据医疗保健利用的社会行为模式选择的:倾向特征(性别、年龄、种族等)、实现特征(社会经济地位、保险状况)、健康状况(疼痛、残疾、合并症等)和医疗保健利用(门诊就诊、急诊就诊和住院)。在 2019 年未使用处方阿片类药物的成年人中,2020 年的 1 年累积发生率为 4.1%(95%置信区间:3.5-4.6),新发生处方阿片类药物使用的发病率(IR)为每 1000 人年 32.6 例。累积发生率、IR 和调整后的相对风险(RR)因参与者特征而异。我们观察到,在疼痛治疗无效的人群中,IR 最高(每 1000 人年 81.6 例),在急诊就诊≥3 次的人群中,IR 最高(每 1000 人年 93.8 例)。报告≥4 种疼痛情况的参与者的调整后 RR 为 2.9(95%置信区间:2.0-4.1),而睡眠问题的 RR 为 2.3(95%置信区间:1.7-3.1)。总体而言,本研究提供了全国范围内新发生处方阿片类药物使用的代表性比率,并表明一些参与者正在将处方阿片类药物作为早期的镇痛药物,这与最佳实践指南相违背。
本纵向队列研究提供了美国成年人和选定亚人群中新发生处方阿片类药物使用的全国代表性比率。我们的数据表明,一些参与者正在将处方阿片类药物作为一线或早期的镇痛药物,这与最佳实践指南相违背。